Multicenter randomized controlled trial to assess the effectiveness of PASSEO-LUX DCB ® drug coated balloon compared to plain balloon angioplasty of arteriovenous fistulae for hemodialysis: Two-years results

气球 血管成形术 医学 血液透析 血液透析通路 动静脉瘘 切割气球 血管通路 外科 放射科 支架 再狭窄
作者
T. Moreno Sánchez,Manuela Moreno‐Ramirez,Francisco Herrero Machancoses
出处
期刊:Journal of Vascular Access [SAGE Publishing]
卷期号:26 (4): 1337-1347 被引量:1
标识
DOI:10.1177/11297298241272259
摘要

Purpose: To compare primary patency after angioplasty with drug-coated balloon (DCB)-Passeo-18Lux, BIOTRONIK versus uncoated balloon in dysfunctional peripheral vascular access (PVA) for hemodialysis. Material and methods: A total of 133 patients from four hospitals were randomized to receive DCB or plain old balloon angioplasty (POBA) after satisfactory treatment (residual stenosis <30%) with high pressure balloon (HPB). The primary endpoint was clinical patency of PVA 2 years after angioplasty. Secondary endpoints included the relationship between the location of stenosis and patency and also, other covariates. Mortality at 2 years was compared between both groups. Results: Patency measured in days after angioplasty was higher in fistulae dilated with DCB than HPB. Kaplan-Meier survival curves showed the next percent of success (free time restenosis) after DCB versus POBA at 6 months—77.1% versus 58.2% (160.41–143.72 days until restenosis), 12 months—51.4% versus 44.3% (274.1–237.23), 18 months—38.6% versus 38% (350.74–305.18), and 24 months—37.1% versus 30.4% (419.04–369.1). At 6 months, this difference was statistically significant ( p = 0.018), but not at 12 ( p = 0.225), 18 ( p = 0.471), or 24 months ( p = 0.236). Mortality was similar in both groups. Conclusions: DCB angioplasty resulted in superior target lesion primary patency (TLPP)-free survival at 6 months of follow-up. No significant improvements in TLPP-free survival long term were observed. Mortality observed at 1 and 2 years was similar in DCB and POBA: there was no significant difference, and a safety study demonstrated no difference between the two groups (complications and mortality): DCB is safe to use in stenosis treatment in patients who are PVA carriers. Level of evidence: Level Ia, therapeutic study, RCT. EBM ratings will be based on a scale of 1–5.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
痴情的玫瑰完成签到,获得积分10
1秒前
科目三应助paojiao不辣采纳,获得10
1秒前
客家老驴完成签到,获得积分10
1秒前
小飞鸡完成签到,获得积分10
1秒前
Kobe发布了新的文献求助10
1秒前
1秒前
1秒前
orixero应助wlu采纳,获得10
1秒前
Lena完成签到,获得积分10
2秒前
zzk发布了新的文献求助10
2秒前
2秒前
茶油豆腐完成签到,获得积分10
3秒前
科研通AI6.4应助phillip521125采纳,获得10
3秒前
AZMARS发布了新的文献求助10
3秒前
jjjcy发布了新的文献求助10
3秒前
Mujuas完成签到,获得积分10
3秒前
完美世界应助Jiangxining采纳,获得10
4秒前
vinni发布了新的文献求助10
4秒前
NexusExplorer应助winwin采纳,获得10
4秒前
HOPE完成签到,获得积分10
4秒前
4秒前
冬天完成签到,获得积分10
5秒前
简单的大哥完成签到,获得积分10
5秒前
高大的老头完成签到,获得积分10
6秒前
6秒前
坡坡大王完成签到,获得积分10
6秒前
文静的白柏完成签到 ,获得积分10
6秒前
6秒前
123完成签到,获得积分10
7秒前
阿熊发布了新的文献求助10
7秒前
cwy完成签到,获得积分10
7秒前
7秒前
7秒前
CodeCraft应助逢彼白雉采纳,获得10
7秒前
8秒前
斯文败类应助ZSZ采纳,获得10
8秒前
程让完成签到,获得积分10
8秒前
冰苏打完成签到,获得积分10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6421818
求助须知:如何正确求助?哪些是违规求助? 8240891
关于积分的说明 17514982
捐赠科研通 5475756
什么是DOI,文献DOI怎么找? 2892653
邀请新用户注册赠送积分活动 1869005
关于科研通互助平台的介绍 1706436